Abstract
Proteins of the Bowman-Birk inhibitor family of serine proteinase inhibitors interact with the enzymes they inhibit via an exposed surface loop that adopts the canonical proteinase inhibitory conformation. The resulting non-covalent complex renders the proteinase inactive. This inhibition mechanism is common for the majority of serine proteinase inhibitor proteins and many analogous examples are known. A particular feature of the Bowman-Birk inhibitor protein, however, is that the interacting loop is a particularly well-defined disulfide-linked short b-sheet region. Moreover, synthetic peptides based on this region keep the same structure as the corresponding part of the full sized protein and also retain inhibitory activity. This review describes the background to inhibition by Bowman-Birk inhibitor proteins (and derived peptides) and shows how peptides based on the reactive site can be manipulated in order to generate potent proteinase inhibitors with redirected specificities.
Keywords: Synthetic Peptide, Bowman-Birk Inhibitor Protein, Bowman-Birk inhibitor (BBI), Inhibition, Structural Analysis, Norleucine
Current Medicinal Chemistry
Title: Synthetic Peptide Mimics of the Bowman-Birk Inhibitor Protein
Volume: 8 Issue: 8
Author(s): Jeffrey D. McBride and Robin J. Leatherbrrow
Affiliation:
Keywords: Synthetic Peptide, Bowman-Birk Inhibitor Protein, Bowman-Birk inhibitor (BBI), Inhibition, Structural Analysis, Norleucine
Abstract: Proteins of the Bowman-Birk inhibitor family of serine proteinase inhibitors interact with the enzymes they inhibit via an exposed surface loop that adopts the canonical proteinase inhibitory conformation. The resulting non-covalent complex renders the proteinase inactive. This inhibition mechanism is common for the majority of serine proteinase inhibitor proteins and many analogous examples are known. A particular feature of the Bowman-Birk inhibitor protein, however, is that the interacting loop is a particularly well-defined disulfide-linked short b-sheet region. Moreover, synthetic peptides based on this region keep the same structure as the corresponding part of the full sized protein and also retain inhibitory activity. This review describes the background to inhibition by Bowman-Birk inhibitor proteins (and derived peptides) and shows how peptides based on the reactive site can be manipulated in order to generate potent proteinase inhibitors with redirected specificities.
Export Options
About this article
Cite this article as:
McBride D. Jeffrey and Leatherbrrow J. Robin, Synthetic Peptide Mimics of the Bowman-Birk Inhibitor Protein, Current Medicinal Chemistry 2001; 8 (8) . https://dx.doi.org/10.2174/0929867013372832
DOI https://dx.doi.org/10.2174/0929867013372832 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine
Current Genomics Chemical and Structural Diversity of siRNA Molecules
Current Topics in Medicinal Chemistry An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design Alpha-Terpineol as Antitumor Candidate in Pre-Clinical Studies
Anti-Cancer Agents in Medicinal Chemistry Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase
Anti-Cancer Agents in Medicinal Chemistry The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents
Current Cancer Drug Targets Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications
Current Cancer Drug Targets Reversal of Tumor Induced Dendritic Cell Paralysis: A Treatment Regimen Against Cancer
Current Immunology Reviews (Discontinued) Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design Interactions of Phenothiazines with Lipid Bilayer and their Role in Multidrug Resistance Reversal
Current Drug Targets Chemical & RNAi Screening at MSKCC: A Collaborative Platform to Discover & Repurpose Drugs to Fight Disease
Combinatorial Chemistry & High Throughput Screening C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry Nerve Growth Factor Receptors and Signaling in Breast Cancer
Current Cancer Drug Targets Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Recent Patents on Nanotechnology Nanogels for Skin Cancer Therapy via Transdermal Delivery: Current Designs
Current Drug Metabolism Molecular Mechanisms of the Action of Myricetin in Cancer
Mini-Reviews in Medicinal Chemistry Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy
Current Cancer Drug Targets